Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 17
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04542057 | A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD | ||
| NCT02307162 | SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects | ||
| NCT02427165 | Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients | ||
| NCT05270525 | Effect of Ensifentrine on Sputum Markers of Inflammation in COPD | ||
| NCT04535986 | A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD | ||
| NCT04091360 | A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease | ||
| NCT02919995 | A Study of RPL554 in Patients With Cystic Fibrosis | ||
| NCT04027439 | Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler | ||
| NCT03443414 | Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients | ||
| NCT03937479 | Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD | ||
| NCT06559150 | A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis | ||
| NCT03028142 | The Effects of RPL554 in Addition to Tiotropium in COPD Patients | ||
| NCT03673670 | Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD | ||
| NCT06545500 | A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD | ||
| NCT06460493 | Effect of Ensifentrine Treatment on CAT Score | ||
| NCT04527471 | Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 | ||
| NCT02542254 | The Effects of RPL554 on Top of Standard COPD Reliever Medications |
